Case Study: Immunogenicity of Natalizumab

  • Meena Subramanyam
Part of the Biotechnology: Pharmaceutical Aspects book series (PHARMASP, volume VIII)


Multiple Sclerosis Expand Disability Status Scale Cynomolgus Monkey Normal Human Serum Monotherapy Study 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Baron, J. L., Madri, J. A., Ruddle, N. H., Hashim, G., and Janeway, C. A. Jr. 1993. Surface expression of α4 integrin by CD4 T cells is required for their entry into brain parenchyma. J. Exp. Med. 177:57–68.PubMedCrossRefGoogle Scholar
  2. Bayless, K. J., Meininger, G. A., Scholtz, J. M., and Davis, G. E. 1998. Osteopontin is a ligand for the α4β1 integrin. J. Cell Sci. 111:1165–1174.PubMedGoogle Scholar
  3. Calabresi, P. A., Giovannoni, G., Confavreux, C., Galetta S. L, Havrdova E, Hutchinson M, Kappos L, Miller DH, O’Connor P. W, Phillips J. T, Polman C. H, Radue E. W, Rudick R. A, Stuart W. H, Lublin F. D, Wajgt A, Weinstock-Guttman B, Wynn D. R, Lynn F, Panzara M. A; AFFIRM and SENTINEL Investigators. 2007. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology. 69:1391–1401.PubMedCrossRefGoogle Scholar
  4. Chabas, D., Baranzini, S. E., Mitchell, D., et al. 2001. The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science 294:1731–1735.PubMedCrossRefGoogle Scholar
  5. Chan, P. Y. and Aruffo, A. 1993. VLA-4 integrin mediates lymphocyte migration on the inducible endothelial cell ligand VCAM-1 and the extracellular matrix ligand fibronectin. J. Biol. Chem. 268:24655–24664.PubMedGoogle Scholar
  6. Davis, L. S., Oppenheimer-Marks, N., Bednarczyk, J. L., McIntyre, B. W., and Lipsky, P. E. 1990. Fibronectin promotes proliferation of naive and memory T cells by signaling through both the VLA-4 and VLA-5 integrin molecules. J. Immunol. 145:785–793.PubMedGoogle Scholar
  7. DeStefano, N., Matthews, P. M., Fu, L., Narayanan, S., Stanley, J., Francis, G. S., Antel, J. P., and Arnold, D. L. 1998. Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. Brain 121:1469–1477.CrossRefGoogle Scholar
  8. Elices, M. J., Osborn, L., Takada, Y., Crouse, C., Luhowskyj, S., Hemler, M. E., and Lobb, R. R. 1990. VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site. Cell 60:577–584.PubMedCrossRefGoogle Scholar
  9. ffrench-Constant, C. 1994. Pathogenesis of multiple sclerosis. Lancet 343:271–275.PubMedCrossRefGoogle Scholar
  10. Freund, M., von Wussow, P., Diedrich, H., Eisert, R., Link, H., Wilke, H., Buchholz, F., Leblanc, S., Fonatsch, C., Deicher, H., and Poliwada, H. 1989. Recombinant human interferon (IFN) alpha-2b in chronic myelogenous leukaemia: dose dependency of response and frequency of neutralizing anti-interferon antibodies. Br. J. Haematol. 72:350–356.PubMedGoogle Scholar
  11. Giannelli, G., Antonelli, G., Fera, G., Del Vecchio, S., Riva, E., Broccia, C., Schiraldi, O., and Dianzani, F. 1994. Biological and clinical significance of neutralizing and binding antibodies to interferon-alpha (IFN-α) during therapy for chronic hepatitis C. Clin. Exp. Immunol. 97:4–9.PubMedCrossRefGoogle Scholar
  12. Kleinschmidt-DeMasters, B. K. and Tyler, K. L. 2005. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N. Engl. J. Med. 353:369–374.PubMedCrossRefGoogle Scholar
  13. Langer-Gould, A., Atlas, S. W., Green, A. J., Bollen, A. W., and Pelletier, D. 2005. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N. Engl. J. Med. 353:375–381.PubMedCrossRefGoogle Scholar
  14. Lobb, R. R. and Hemler, M. E. 1994. The pathophysiologic role of alpha 4 integrins in vivo. J. Clin. Invest. 94:1722–1728.PubMedCrossRefGoogle Scholar
  15. Lublin, F. D. 2005. Multiple sclerosis trial designs for the 21st century: building on recent lessons. J. Neurol. 252(Suppl. 5):46–53.CrossRefGoogle Scholar
  16. Meager, A. 1994. Human antibodies to insulin in diabetes. J. Interferon Res. 14:181–182.PubMedGoogle Scholar
  17. Miller, D. H., Khan, O. A., Sheremata, W. A,. Blumhardt, L. D., Rice, G. P., Libonati, M. A., Willmer-Hulme, A.J., Dalton, C. M., Miszkiel, K. A., and O’ Connor, P. W. 2003. A controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 348:15–23.PubMedCrossRefGoogle Scholar
  18. Mould, A. P., Wheldon, L. A., Komoriya, A., Wayner, E. A., Yamada, K. M., and Humphries, M. J. 1990. Affinity chromatographic isolation of the melanoma adhesion receptor for the IIICS region of fibronectin and its identification as the integrin alpha 4 beta 1. J. Biol. Chem. 265:4020–4024.PubMedGoogle Scholar
  19. O’Regan, A. W., Chupp, G. L., Lowry, J.A., Goetschkes M., Mulligan, N., and Berman, J. S. 1999. Osteopontin is associated wit T cells in sarcoid granulomas and has T cell adhesive and cytokine-like properties in vitro. J. Immunol. 162: 1024–1031.PubMedGoogle Scholar
  20. Polman, C. H., O’Connor, P. W., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D. H., Phillips, J. T., Lublin, F. D., Giovannoni, G., Wajgt, A., Toal, M., Lynn, F., Panzara, M. A., and Sandrock, A. W. 2006. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 354:899–910.PubMedCrossRefGoogle Scholar
  21. Rudick, R. A., Stuart, W. H., Calabresi, P.A., Confavreux, C., Galetta, S. L., Radue, E. W., Lublin, F. D., Weinstock-Guttman, B., Wynn, D. R., Lynn, F., Panzara, M. A., and Sandrock, A. W. 2006. Natalizumab plus interferon beta-1 for relapsing multiple sclerosis. N. Engl. J. Med. 354:911–923.PubMedCrossRefGoogle Scholar
  22. Rudick, R. A. and Sandrock A. 2004. Natalizumab: α4-integrin antagonist selective adhesion molecule inhibitors for MS. Expert Rev. Neurotherapeutics 4:571–580.CrossRefGoogle Scholar
  23. Schellekens, H. 2002 Bioequivalence and the immunogenicity of biopharmaceuticals. Nat. Rev. 1:457–462.Google Scholar
  24. Sheremata, W. A., Vollmer, T. L., Stone, L. A., Willmer-Hulme, A. J., and Koller, M. A. 1999. A safety and pharmacokinetic study of intravenous natalizumab in patients with MS. Neurology 52:1072–1074.Google Scholar
  25. Tysabri Product Information. 2006. Biogen Idec Inc, Cambridge, MA.Google Scholar
  26. Van Assche, G., Van Ranst, M., Sciot, R., Dubois, B., Vermeire, S., Noman, M., Verbeeck, J., Geboes, K., Robberecht, W., and Rutgeerts, P. 2005. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N. Engl. J. Med. 353:362–368.PubMedCrossRefGoogle Scholar
  27. Weinshenker, B. G., Bass, B., Rice, G. P. A., Noseworthy, J., Carriere, W., Baskerville, J., and Ebers, G. C. 1989. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 112:133–146.Google Scholar
  28. Wolinsky, J. S. 2003. Rational therapy for relapsing multiple sclerosis. Lancet Neurol. 2:271–272.PubMedCrossRefGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2008

Authors and Affiliations

  • Meena Subramanyam

There are no affiliations available

Personalised recommendations